MoveByBike Europe AB (”MoveByBike” eller ”Bolaget”) är ett hållbart logistikföretag som erbjuder hål...
Redeye provides a comment on Nanologica following the announcement of another order (marking the fou...
Hansa’s partner Genethon initiates a phase 2 study based on Imlifidase as a pre-treatment ahead of G...
Redeye sees a Q2 report in line with our sales expectations but a bit heavier on the cost side.
Redeye leaves a comment following the promising recent interim data from Faron’s BEXMAB study and in...
The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) ...
Contemplates issuance of SEK 250m bond (500m framework) Refinance of the SEK 250m bond issued in Q4'...
Sales of SEK 49m -38% q-o-q, EBIT back to negative at SEK -8m We lower FY'24/25e-FY'26/27e sales by ...
ODI Pharma AB:s (”ODI Pharma” or the ”Company”) latest quarter was affected by import restrictions i...
STENOCARE announced on December 2nd that the company’s premium product, the Astrum oil, has been app...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har under och efter utgången av...
Solwers posted Q3 2024 revenue growth of 21% y/y, entirely driven by acquisitions.
Redeye has a positive view of Tagmaster’s acquisition.
Divests four service-oriented Infra units for SEK 714m consideration Accelerates transition to highe...
Irisity AB (”Irisity” or ”the Company”) announced, on the 28th of November, the outcome of the right...
